SOSV

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Synplexity, based in New Castle, Delaware, specializes in biotechnology. It offers mutational scanning and multiplexed gene synthesis services, leveraging artificial intelligence. The company's platform, utilizing microdroplets as microreactors, enables the creation of multiplex gene libraries, benefiting various sectors such as therapeutics, biomanufacturing, agriculture, and climate systems.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the healthcare industry to treat complex diseases such as cancers and age-related disorders more effectively.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

ArgenTag is a biotech startup focused on democratizing genomic sequencing through innovative technology. The company has developed a robust solution that significantly reduces the costs associated with long-read sequencing applications. By integrating micro-fabrication, next-generation DNA sequencing, molecular biology, and mechanical engineering, ArgenTag's platform produces synthetic DNA barcodes, allowing for the simultaneous sequencing of thousands of samples. This technology enables medical professionals to analyze antibodies and perform single-cell sequencing, making advanced genomic analysis more accessible to a broader audience.

ArgenTag is a biotech startup focused on democratizing genomic sequencing through innovative technology. The company has developed a robust solution that significantly reduces the costs associated with long-read sequencing applications. By integrating micro-fabrication, next-generation DNA sequencing, molecular biology, and mechanical engineering, ArgenTag's platform produces synthetic DNA barcodes, allowing for the simultaneous sequencing of thousands of samples. This technology enables medical professionals to analyze antibodies and perform single-cell sequencing, making advanced genomic analysis more accessible to a broader audience.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

CyGenica specializes in developing innovative delivery solutions for drugs, gene editing components, and antibiotics using a non-viral, non-toxic platform. The company focuses on creating molecular devices that facilitate the programmable delivery of anticancer drugs and other therapeutic agents directly into cells. These devices are designed to cross cellular membrane barriers, allowing for the effective transport of functional molecules into the cytoplasm and various cellular organelles. By enabling pharmaceutical and biotechnology companies to develop new types of anticancer drugs with extended brand lifecycles, CyGenica aims to enhance the efficacy and safety of medical treatments.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Synthetix is a decentralized synthetic asset issuance protocol based in Australia, established in 2017 by Kain Warwick. Built on the Ethereum blockchain, it facilitates derivatives trading in decentralized finance (DeFi) by enabling the creation of synthetic assets that provide exposure to real-world currencies, commodities, stocks, and indices. The platform offers unique financial instruments such as perpetual futures and options markets, allowing users to trade synthetic forms of assets with infinite liquidity. Synthetix operates a peer-to-contract trading system and utilizes a distributed collateral pool, ensuring transparency and accessibility for customers seeking on-chain exposure to various decentralized assets.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Pando Nutrition, Inc. is an animal microbiome company focused on developing innovative probiotics to support antibiotic-free livestock production. Based in San Francisco, California, and incorporated in 2017, the company aims to address the antibiotic resistance crisis by utilizing genetically engineered probiotics that enhance livestock health and performance without relying on medically significant drugs. Pando Nutrition offers Panbiotics, a platform designed to identify and control methane emissions, thereby improving feed efficiency and profitability in livestock. Additionally, the company is engaged in the development of solutions for poultry pathogens, such as Coccidiosis. By leveraging advanced biotechnology, Pando Nutrition creates yeast-based systems for animal feed that not only boost animal health and immunity but also enable the production of essential nutrients, contributing to a sustainable and efficient food supply chain.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Helixworks Technologies, established in 2016 and headquartered in Cork, Ireland, specializes in biotechnology. The company manufactures molecular storage systems, utilizing DNA (Deoxyribonucleic acid) as a medium to store digital information. Their open architecture platform aims to simplify and streamline this process, making it accessible to developers working on applications such as digital preservation, molecular tagging, and advanced barcoding for Next-Generation Sequencing (NGS). Helixworks' mission is to transition biology into an engineering principle, ultimately enabling the creation of living machines.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Chronomics Ltd is a tech-bio company based in Norwich, United Kingdom, founded in 2017. It specializes in manufacturing testing kits and developing an artificial intelligence platform for DNA methylation analysis. The company provides insights into biological age, smoke exposure, metabolic state, health risks, eye color, and hereditary intolerance. Chronomics aims to make biological information more accessible and actionable, addressing the complexities and costs associated with obtaining such data. By creating bio-infrastructure across various sectors, the company enhances the use of biomarkers to inform everyday decisions in areas such as telehealth, travel, and wellness. Through partnerships with major organizations, Chronomics seeks to transform the way biological information is utilized for diagnosis, personalization, and evaluation of health-related offerings.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

Osiris Bio

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Biomathematica is a biotechnology start-up that specializes in advanced modeling services aimed at characterizing and understanding biological processes. The company offers genome-scale metabolic models that facilitate the simulation, monitoring, control, optimization, and modification of biological behaviors. By focusing on microbiome-related genomic data analysis, Biomathematica provides quantitative and predictive insights that assist biotechnology and pharmaceutical companies in navigating therapeutics and disease areas associated with the microbiome. Through its innovative approaches, Biomathematica aims to enhance business outcomes by bridging the gap between genomic data and practical applications in the life sciences sector.

Chronomics Ltd is a tech-bio company based in Norwich, United Kingdom, founded in 2017. It specializes in manufacturing testing kits and developing an artificial intelligence platform for DNA methylation analysis. The company provides insights into biological age, smoke exposure, metabolic state, health risks, eye color, and hereditary intolerance. Chronomics aims to make biological information more accessible and actionable, addressing the complexities and costs associated with obtaining such data. By creating bio-infrastructure across various sectors, the company enhances the use of biomarkers to inform everyday decisions in areas such as telehealth, travel, and wellness. Through partnerships with major organizations, Chronomics seeks to transform the way biological information is utilized for diagnosis, personalization, and evaluation of health-related offerings.

Sun Genomics, Inc. is a microbiome health company based in San Diego, California, specializing in customized probiotics aimed at addressing dysbiosis. Founded in 2014, the company’s flagship product, Floré, combines a gut microbiome test with personalized probiotic formulations tailored to individual gut profiles, assessed through whole-genome sequencing. The Floré Gut Test includes a microflora collection kit, a comprehensive microflora profile analysis, and wellness consultations. Additionally, Sun Genomics offers Floré Tots, a probiotic solution designed for children up to age 12, which comes in a convenient powder form that can be easily mixed with beverages. The company sells its products online, providing an automatic renewal service to enhance customer convenience.

Cell-Free Technology Limited, established in 2017 and located in Cork, Ireland, specializes in the production of cell-free extracts that enable the synthesis of essential biomolecules, such as insulin, odors, bio-compatible color palettes, and fluorescent proteins. This innovative approach allows for cell-free protein expression, facilitating the creation of biological products without the constraints of traditional laboratory settings or regulations related to genetic modification. The company offers ultra low-cost cell-free extracts and kits designed to simplify biological production, making it accessible for various applications outside conventional labs. Additionally, Cell-Free Technology is committed to open-source projects, actively sharing resources to promote wider use and understanding of their technology.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Onconetics Pharmaceuticals, Inc. is a biotechnology company based in Mill Valley, California, focused on developing personalized gene therapies for cancer and other genetic disorders. Established in 2016, the company employs a unique therapeutic platform that utilizes a genetic switch to activate an apoptotic inducer, selectively targeting and eliminating tumor cells while preserving healthy tissue. This innovative approach combines established gene therapy techniques with advanced research to create treatments that aim to improve patient outcomes by reducing the invasiveness and side effects associated with traditional therapies. Onconetics seeks to advance the field of personalized medicine by offering simpler, versatile therapies that prioritize patient safety and quality of life.

PLANTeDIT Limited is a biotech company based in Cork, Ireland, founded in 2017. It specializes in developing advanced plant transformation technologies that utilize CRISPR/Cas9 RNPs for the direct delivery and regeneration of genome-edited plants and biopharmaceuticals. The company focuses on producing non-transgenic, regulatory-free, and sustainable plant products, such as high oleic soya, aimed at consumer health and preferences. PLANTeDIT's innovative approach allows for the creation of DNA-free crops, enabling the production of pure mammalian proteins and human drugs at competitive prices through its genome-edited plant platform. The company also collaborates strategically with Toolgen to enhance its research and development efforts.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Cell-Free Technology Limited, established in 2017 and located in Cork, Ireland, specializes in the production of cell-free extracts that enable the synthesis of essential biomolecules, such as insulin, odors, bio-compatible color palettes, and fluorescent proteins. This innovative approach allows for cell-free protein expression, facilitating the creation of biological products without the constraints of traditional laboratory settings or regulations related to genetic modification. The company offers ultra low-cost cell-free extracts and kits designed to simplify biological production, making it accessible for various applications outside conventional labs. Additionally, Cell-Free Technology is committed to open-source projects, actively sharing resources to promote wider use and understanding of their technology.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative treatments for incurable cancers and neurodegenerative diseases. Founded in 2017 and based in San Diego, California, the company utilizes a machine vision and learning platform to drive diseased stem cells toward non-diseased states. Its proprietary technology, known as microscopic imaging of epigenetic landscapes (MIEL), facilitates the discovery of small molecules that can induce epigenetic changes, allowing for the differentiation or reversal of cancerous cells into benign types, which holds potential for curative outcomes. Additionally, Stelvio is pursuing a personalized approach to glioblastoma treatment, leveraging its team's expertise in scientific innovation and clinical management to advance novel drug therapies and precision medicine diagnostics.

PLANTeDIT Limited is a biotech company based in Cork, Ireland, founded in 2017. It specializes in developing advanced plant transformation technologies that utilize CRISPR/Cas9 RNPs for the direct delivery and regeneration of genome-edited plants and biopharmaceuticals. The company focuses on producing non-transgenic, regulatory-free, and sustainable plant products, such as high oleic soya, aimed at consumer health and preferences. PLANTeDIT's innovative approach allows for the creation of DNA-free crops, enabling the production of pure mammalian proteins and human drugs at competitive prices through its genome-edited plant platform. The company also collaborates strategically with Toolgen to enhance its research and development efforts.

Helixworks Technologies, established in 2016 and headquartered in Cork, Ireland, specializes in biotechnology. The company manufactures molecular storage systems, utilizing DNA (Deoxyribonucleic acid) as a medium to store digital information. Their open architecture platform aims to simplify and streamline this process, making it accessible to developers working on applications such as digital preservation, molecular tagging, and advanced barcoding for Next-Generation Sequencing (NGS). Helixworks' mission is to transition biology into an engineering principle, ultimately enabling the creation of living machines.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Jungla Inc., headquartered in South San Francisco, is a biotechnology company focused on enhancing disease diagnosis and drug development through its molecular function software platform. Established in 2016, the company integrates advancements in functional genomics, computational biophysics, and computer science to provide healthcare and drug companies with quantitative, model-driven insights into genomic variants. This innovative approach aims to improve the accuracy of clinical genetic testing, addressing shortcomings in existing market solutions. By delivering robust and scalable results, Jungla empowers healthcare providers to expedite diagnostic development and treatment processes. As a subsidiary of Invitae Corporation, Jungla is supported by prominent technology and healthcare investors, reflecting its commitment to advancing precision medicine.

Ravata Solutions, founded in 2016 and based in Davis, California, specializes in developing medical devices for gene delivery, focusing on the creation of custom animal models. The company is dedicated to enhancing the production of transgenic models, which are crucial for pre-clinical research studies aimed at improving human disease modeling. By optimizing embryo viability and streamlining the process of creating transgenic organisms, Ravata enables researchers to conduct their studies more efficiently. This innovation has significant implications for advancing drug efficacy and medical genetics research, ultimately contributing to the development of better therapies and understanding of human diseases.